Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia

Aljunid, Syed, Abuduxike, Gulifeiya, Ahmed, Zafar, Sulong, Saperi, Nur, Amrizal Muhd and Goh, Adrian (2011) Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. BMC Infectious Diseases, 11 (1). p. 248. ISSN 1471-2334

1471-2334-11-248.pdf - Published Version
Available under License Creative Commons Attribution 4.0.

Download (195kB) | Preview
Official URL:


Background: Pneumococcal disease is the leading cause of vaccine-preventable death in children younger than 5 years of age worldwide. The World Health Organization recommends pneumococcal conjugate vaccine as a priority for inclusion into national childhood immunization programmes. Pneumococcal vaccine has yet to be included as part of the national vaccination programme in Malaysia although it has been available in the country since 2005. This study sought to estimate the disease burden of pneumococcal disease in Malaysia and to assess the cost effectiveness of routine infant vaccination with PCV7.Methods: A decision model was adapted taking into consideration prevalence, disease burden, treatment costs and outcomes for pneumococcal disease severe enough to result in a hospital admission. Disease burden were estimated from the medical records of 6 hospitals. Where local data was unavailable, model inputs were obtained from international and regional studies and from focus group discussions. The model incorporated the effects of herd protection on the unvaccinated adult population.Results: At current vaccine prices, PCV7 vaccination of 90% of a hypothetical 550,000 birth cohort would incur costs of RM 439.6 million (US$128 million). Over a 10 year time horizon, vaccination would reduce episodes of pneumococcal hospitalisation by 9,585 cases to 73,845 hospitalisations with cost savings of RM 37.5 million (US$10.9 million) to the health system with 11,422.5 life years saved at a cost effectiveness ratio of RM 35,196 (US$10,261) per life year gained.Conclusions: PCV7 vaccination of infants is expected to be cost-effective for Malaysia with an incremental cost per life year gained of RM 35,196 (US$10,261). This is well below the WHO's threshold for cost effectiveness of public health interventions in Malaysia of RM 71,761 (US$20,922).

Item Type: Article
Additional Information: Funding Information: We wish to thank the Director General of Health, Malaysia for permission to publish this paper. We would like to thank Drs Hasniah Abdul Latiff and Fauzi Mohd. Anshar of UKM Medical Centre, Drs Mohd Suhaimi Ab. Wahab and Shaharuddin Abdullah of Hospital Universiti Sains Malaysia, Dr. Chin Choy Nyok and Dato’ Dr. Haji Sapari Satwi of Hospital Tengku Ampuan Afzan, Dato’ Dr. Teh Keng Hwang and Dr. Mustafa Kamal Razak of Hospital Sultanah Bahiyah, Alor Setar, Drs Tan Kah Kee and Vijiya Mala of Hospital Tuanku Ja’afar, Seremban, and Drs Chan Lee Gaik and Kalwinder Singh Khaira of Sarawak General Hospital for their assistance during primary data collection. The preparation and publication of this manuscript was funded by a grant from Pfizer (M) Sdn Bhd.
Uncontrolled Keywords: Otitis Medium, Invasive Pneumococcal Disease, Pneumococcal Disease, Pneumococcal Meningitis, Herd Effect
Subjects: A300 Clinical Medicine
Department: Faculties > Health and Life Sciences > Social Work, Education and Community Wellbeing
Depositing User: Rachel Branson
Date Deposited: 15 Dec 2022 12:11
Last Modified: 15 Dec 2022 12:15

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics